Sign In
Buy INO
$1.14
-0.0700 (-5.79%)
At Close: Jun 03, 2026
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022
02:02pm, Wednesday, 11'th May 2022 Benzinga
Upgrades
According to Roth Capital, the prior rating for Hecla Mining Co (NYSE:HL) was changed from Neutral to Buy. In the first quarter, Hecla Mining showed an EPS of $0.01, compared to $0.06 from th
INO Stock Plunges 25% as Inovio Pharmaceuticals Swaps Vaccine Focus
12:05pm, Wednesday, 11'th May 2022
Inovio Pharmaceuticals has halted its Covid-19 progress to focus on a booster. Here's why this news is unlikely to boost INO stock.
Inovio lets go of CEO, to stop work on COVID-19 vaccine and instead focus on booster
08:16am, Wednesday, 11'th May 2022
Inovio Pharmaceuticals Inc.'s INO, +5.06% stock tumbled 21.7% in premarket trading on Wednesday, the day after the company said it will discontinue its work on a COVID-19 vaccine and will instead focu
Inovio Pharmaceuticals (INO) Q1 2022 Earnings Call Transcript
04:00am, Wednesday, 11'th May 2022 The Motley Fool
INO earnings call for the period ending March 31, 2022.
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Lags Revenue Estimates
09:35pm, Tuesday, 10'th May 2022 Zacks Investment Research
Inovio (INO) delivered earnings and revenue surprises of -28.57% and 56.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Lags Revenue Estimates
06:49pm, Tuesday, 10'th May 2022
Inovio (INO) delivered earnings and revenue surprises of -28.57% and 56.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Biogen Inc. (BIIB) Q1 Earnings Miss Estimates
12:25pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Biogen Inc. (BIIB) delivered earnings and revenue surprises of -17.91% and 1.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Repligen (RGEN) Beats Q1 Earnings and Revenue Estimates
12:45pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Repligen (RGEN) delivered earnings and revenue surprises of 27.78% and 12.45%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
2 Contenders in the Coronavirus Vaccine Market -- Are They Buys?
03:30pm, Monday, 25'th Apr 2022 The Motley Fool
These two companies have been left in the dust. Is it too late for them?
Inovio: Long-Term Biotech To Own With Several Catalysts Expected In 2022
01:13pm, Friday, 15'th Apr 2022
Primary and secondary endpoints met in late-stage REVEAL 1 which used VGX-3100 for women with HSIL. Results form the second late-stage study REVEAL 2, using VGX-3100 for women with HSIL, expected in Q
2 Beaten-Down Stocks That Aren't Worth the Trouble
03:45pm, Wednesday, 16'th Mar 2022 The Motley Fool
Some cheap stocks aren't bargains.
Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim Presents at Oppenheimer''s 32nd Annual Healthcare Conference (Transcript)
05:47pm, Tuesday, 15'th Mar 2022 Seeking AlphaInovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim Presents at Oppenheimer's 32nd Annual Healthcare Conference (Transcript)
01:47pm, Tuesday, 15'th Mar 2022
Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim Presents at Oppenheimer's 32nd Annual Healthcare Conference (Transcript)
Could Inovio Win On This 1 Vaccine Detail?
11:00am, Tuesday, 08'th Mar 2022 The Motley Fool
This vaccine laggard suffered a new setback -- but there is one piece of good news.
SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying
02:49pm, Monday, 07'th Mar 2022
SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying
